These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24283962)

  • 21. Dementia in 2014. Towards early diagnosis in Alzheimer disease.
    Nordberg A
    Nat Rev Neurol; 2015 Feb; 11(2):69-70. PubMed ID: 25623789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.
    Villemagne VL; Doré V; Burnham SC; Masters CL; Rowe CC
    Nat Rev Neurol; 2018 Apr; 14(4):225-236. PubMed ID: 29449700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer's disease.
    Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
    Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
    Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers.
    Morbelli S; Bauckneht M
    Methods Mol Biol; 2018; 1750():203-212. PubMed ID: 29512074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
    Carapelle E; Serra L; Modoni S; Falcone M; Caltagirone C; Bozzali M; Specchio LM; Avolio C
    Medicine (Baltimore); 2017 Apr; 96(16):e5876. PubMed ID: 28422821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers study in atypical dementia: proof of a diagnostic work-up.
    Lombardi G; Polito C; Berti V; Ferrari C; Lucidi G; Bagnoli S; Piaceri I; Nacmias B; Pupi A; Sorbi S
    Neurol Sci; 2018 Jul; 39(7):1203-1210. PubMed ID: 29651720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic interaction between amyloid and tau predicts the progression to dementia.
    Pascoal TA; Mathotaarachchi S; Shin M; Benedet AL; Mohades S; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P;
    Alzheimers Dement; 2017 Jun; 13(6):644-653. PubMed ID: 28024995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of positron emission tomography/computed tomography in dementia.
    Hinds SR; Stocker DJ; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):927-34. PubMed ID: 24010914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPECT and PET imaging in Alzheimer's disease.
    Valotassiou V; Malamitsi J; Papatriantafyllou J; Dardiotis E; Tsougos I; Psimadas D; Alexiou S; Hadjigeorgiou G; Georgoulias P
    Ann Nucl Med; 2018 Nov; 32(9):583-593. PubMed ID: 30128693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
    J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.
    Segovia F; Gómez-Río M; Sánchez-Vañó R; Górriz JM; Ramírez J; Triviño-Ibáñez E; Carnero-Pardo C; Martínez-Lozano MD; Sopena-Novales P
    J Alzheimers Dis; 2018; 65(3):765-779. PubMed ID: 30103321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies.
    Dukart J; Mueller K; Horstmann A; Vogt B; Frisch S; Barthel H; Becker G; Möller HE; Villringer A; Sabri O; Schroeter ML
    Neuroimage; 2010 Jan; 49(2):1490-5. PubMed ID: 19770055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Garibotto V; Herholz K; Boccardi M; Picco A; Varrone A; Nordberg A; Nobili F; Ratib O;
    Neurobiol Aging; 2017 Apr; 52():183-195. PubMed ID: 28317648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aβ-amyloid and Tau Imaging in Dementia.
    Villemagne VL; Doré V; Bourgeat P; Burnham SC; Laws S; Salvado O; Masters CL; Rowe CC
    Semin Nucl Med; 2017 Jan; 47(1):75-88. PubMed ID: 27987560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
    Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.